Clinical pharmacology of novel anti-Alzheimer disease modifying medications

Filippo Caraci, Paolo Bosco, Gian Marco Leggio, Michele Malaguarnera, Filippo Drago, Claudio Bucolo, Salvatore Salomone

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In recent years, efforts have been directed to develop "disease-modifying" medications to treat Alzheimer's disease (AD), able to halt or slow the pathological process. Because the earlier the treatment starts, the greater is the possibility of efficacy, it is important to set up biomarkers for early diagnosis of functional brain abnormalities, before the clinical manifestation of the overt disease. Up to now, strategies to develop disease-modifying drugs have mainly targeted β amyloid (Aβ, accumulation, aggregation, clearance) and/or tau protein (phosphorylation and aggregation). Active and passive immunotherapy is the main strategy aimed at increasing Aβ clearance. Unfortunately several candidate diseasemodifying drugs have failed in phase III clinical trials conducted in mild to moderate AD. More recently, in phase III studies, bapineuzumab has been discontinued because it did not prove clinically effective (despite its significant effect on biomarkers), while solaneuzumab has been found effective in slowing AD progression. Several methological problems have been recently pointed out to explain the lack of clinical efficacy of novel disease-modifying drug-treatments; moreover, new insights in pathophysiology of AD give the premise to develop novel drug targeting. Clinical trials recently completed and/or still ongoing are discussed in the present review.

Original languageEnglish
Pages (from-to)1853-1863
Number of pages11
JournalCurrent Topics in Medicinal Chemistry
Volume13
Issue number15
Publication statusPublished - 2013

Fingerprint

Clinical Pharmacology
Alzheimer Disease
Biomarkers
Pharmaceutical Preparations
Active Immunotherapy
tau Proteins
Phase III Clinical Trials
Passive Immunization
Pathologic Processes
Drug Delivery Systems
Amyloid
Disease Progression
Early Diagnosis
Phosphorylation
Clinical Trials
Brain
Therapeutics

Keywords

  • β-amyloid
  • Alzheimer's disease
  • Clinical trials
  • Disease-modifying drug

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013). Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Current Topics in Medicinal Chemistry, 13(15), 1853-1863.

Clinical pharmacology of novel anti-Alzheimer disease modifying medications. / Caraci, Filippo; Bosco, Paolo; Leggio, Gian Marco; Malaguarnera, Michele; Drago, Filippo; Bucolo, Claudio; Salomone, Salvatore.

In: Current Topics in Medicinal Chemistry, Vol. 13, No. 15, 2013, p. 1853-1863.

Research output: Contribution to journalArticle

Caraci, F, Bosco, P, Leggio, GM, Malaguarnera, M, Drago, F, Bucolo, C & Salomone, S 2013, 'Clinical pharmacology of novel anti-Alzheimer disease modifying medications', Current Topics in Medicinal Chemistry, vol. 13, no. 15, pp. 1853-1863.
Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C et al. Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Current Topics in Medicinal Chemistry. 2013;13(15):1853-1863.
Caraci, Filippo ; Bosco, Paolo ; Leggio, Gian Marco ; Malaguarnera, Michele ; Drago, Filippo ; Bucolo, Claudio ; Salomone, Salvatore. / Clinical pharmacology of novel anti-Alzheimer disease modifying medications. In: Current Topics in Medicinal Chemistry. 2013 ; Vol. 13, No. 15. pp. 1853-1863.
@article{422c50c6be4148f480e0fc8b3bb5451a,
title = "Clinical pharmacology of novel anti-Alzheimer disease modifying medications",
abstract = "In recent years, efforts have been directed to develop {"}disease-modifying{"} medications to treat Alzheimer's disease (AD), able to halt or slow the pathological process. Because the earlier the treatment starts, the greater is the possibility of efficacy, it is important to set up biomarkers for early diagnosis of functional brain abnormalities, before the clinical manifestation of the overt disease. Up to now, strategies to develop disease-modifying drugs have mainly targeted β amyloid (Aβ, accumulation, aggregation, clearance) and/or tau protein (phosphorylation and aggregation). Active and passive immunotherapy is the main strategy aimed at increasing Aβ clearance. Unfortunately several candidate diseasemodifying drugs have failed in phase III clinical trials conducted in mild to moderate AD. More recently, in phase III studies, bapineuzumab has been discontinued because it did not prove clinically effective (despite its significant effect on biomarkers), while solaneuzumab has been found effective in slowing AD progression. Several methological problems have been recently pointed out to explain the lack of clinical efficacy of novel disease-modifying drug-treatments; moreover, new insights in pathophysiology of AD give the premise to develop novel drug targeting. Clinical trials recently completed and/or still ongoing are discussed in the present review.",
keywords = "β-amyloid, Alzheimer's disease, Clinical trials, Disease-modifying drug",
author = "Filippo Caraci and Paolo Bosco and Leggio, {Gian Marco} and Michele Malaguarnera and Filippo Drago and Claudio Bucolo and Salvatore Salomone",
year = "2013",
language = "English",
volume = "13",
pages = "1853--1863",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Clinical pharmacology of novel anti-Alzheimer disease modifying medications

AU - Caraci, Filippo

AU - Bosco, Paolo

AU - Leggio, Gian Marco

AU - Malaguarnera, Michele

AU - Drago, Filippo

AU - Bucolo, Claudio

AU - Salomone, Salvatore

PY - 2013

Y1 - 2013

N2 - In recent years, efforts have been directed to develop "disease-modifying" medications to treat Alzheimer's disease (AD), able to halt or slow the pathological process. Because the earlier the treatment starts, the greater is the possibility of efficacy, it is important to set up biomarkers for early diagnosis of functional brain abnormalities, before the clinical manifestation of the overt disease. Up to now, strategies to develop disease-modifying drugs have mainly targeted β amyloid (Aβ, accumulation, aggregation, clearance) and/or tau protein (phosphorylation and aggregation). Active and passive immunotherapy is the main strategy aimed at increasing Aβ clearance. Unfortunately several candidate diseasemodifying drugs have failed in phase III clinical trials conducted in mild to moderate AD. More recently, in phase III studies, bapineuzumab has been discontinued because it did not prove clinically effective (despite its significant effect on biomarkers), while solaneuzumab has been found effective in slowing AD progression. Several methological problems have been recently pointed out to explain the lack of clinical efficacy of novel disease-modifying drug-treatments; moreover, new insights in pathophysiology of AD give the premise to develop novel drug targeting. Clinical trials recently completed and/or still ongoing are discussed in the present review.

AB - In recent years, efforts have been directed to develop "disease-modifying" medications to treat Alzheimer's disease (AD), able to halt or slow the pathological process. Because the earlier the treatment starts, the greater is the possibility of efficacy, it is important to set up biomarkers for early diagnosis of functional brain abnormalities, before the clinical manifestation of the overt disease. Up to now, strategies to develop disease-modifying drugs have mainly targeted β amyloid (Aβ, accumulation, aggregation, clearance) and/or tau protein (phosphorylation and aggregation). Active and passive immunotherapy is the main strategy aimed at increasing Aβ clearance. Unfortunately several candidate diseasemodifying drugs have failed in phase III clinical trials conducted in mild to moderate AD. More recently, in phase III studies, bapineuzumab has been discontinued because it did not prove clinically effective (despite its significant effect on biomarkers), while solaneuzumab has been found effective in slowing AD progression. Several methological problems have been recently pointed out to explain the lack of clinical efficacy of novel disease-modifying drug-treatments; moreover, new insights in pathophysiology of AD give the premise to develop novel drug targeting. Clinical trials recently completed and/or still ongoing are discussed in the present review.

KW - β-amyloid

KW - Alzheimer's disease

KW - Clinical trials

KW - Disease-modifying drug

UR - http://www.scopus.com/inward/record.url?scp=84887942754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887942754&partnerID=8YFLogxK

M3 - Article

C2 - 23931438

AN - SCOPUS:84887942754

VL - 13

SP - 1853

EP - 1863

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 15

ER -